Fascia Iliaca Block Using Liposomal Bupivacaine for Analgesia After Hip Fracture Surgery (NCT07643792) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Fascia Iliaca Block Using Liposomal Bupivacaine for Analgesia After Hip Fracture Surgery
China148 participantsStarted 2026-07
Plain-language summary
Older patients with hip fractures often suffer from severe pain. Inadequate analgesia increases the risk of postoperative delirium, myocardial injury, and other complications. Peripheral nerve block is an important component of multimodal analgesia, but conventional local anesthetics (such as plain bupivacaine) provide only approximately 12 hours of analgesic duration, which is far from covering the most painful 72 hours after surgery. Liposomal bupivacaine has a slow-release property, prolonging the analgesic duration up to 72 hours after a single injection. However, its clinical advantages in hip fracture surgery remain controversial. The investigators suppose that, compared with plain bupivacaine alone, preoperative supra-inguinal fascia iliaca block using liposomal bupivacaine combined with plain bupivacaine can further improve analgesia, decrease opioid consumption, and improve postoperative recovery quality within 72 hours in older patients after hip fracture surgery.
Who can participate
Age range
55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged ≥ 55 years.
* Diagnosed as hip fracture and scheduled to undergo hip replacement surgery.
* Agree to receive regional nerve block and postoperative patient-controlled intravenous analgesia (PCIA).
Exclusion Criteria:
* Inability to communicate due to visual, auditory, language, or other reasons before surgery.
* Chronic opioid dependence and long-term use of various types of analgesics (for more than 3 months).
* Severe coagulation abnormalities (International Normalized Ratio \> 1.7, activated partial thromboplastin time exceeding the normal value by more than 4 seconds, platelet count \< 80 × 10⁹/L), trauma or infection at the intended puncture site, or severe low back pain.
* Preoperative severe renal insufficiency (serum creatinine \> 442 μmol/L or requiring renal replacement therapy), hepatic insufficiency (Child-Pugh class C), or ASA physical status \> IV.
* Known allergy to local anesthetics.
* Any other condition that the investigator or attending physician deems unsuitable for participation in the study.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The area under curve of pain intensity within 72 hours after surgery